Resources

In part 1 of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the concept of trans-cultural endocrinology and why it is essential to understand how differences in culture can impact diabetes care.

In part 2 of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about trans-cultural endocrinology in America and how doctors can take patient culture into account when planning individualized care.

In part 3 of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about gaps in current knowledge of how medications impact different ethnic populations, and how AACE is working to educate providers on these gaps.

In part 4 of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about trans-cultural drivers in type 2 diabetes, such as different eating patterns in different cultures.

In part 5 of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about the need for lifestyle medicine in treating diabetes, and how new multidisciplinary approaches are balancing nutrition vs physical activity in diabetes care.

In part 6 of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about why the prevention of diabetes complications faces challenges, and how behavioral medicine may help change that.

In part 7, the conclusion of this Exclusive Interview, Dr. Jeffrey Mechanick talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston, MA about his key takeaways for healthcare providers and how they can incorporate cultural awareness in diabetes treatment.

New meta-analysis striving to expand on the notion that glycemic control and stroke risk are closely associated.

Sotagliflozin to be reviewed by the FDA as possible oral adjunct for people with insulin-treated type 1 diabetes.

Discrepancies prompt additional analyses of ACCORD-BP and SPRINT studies to determine best blood pressure target for those with diabetes.